Brain computer interface company
Synchron is a clinical-stage neurovascular bioelectronics medicine company. The company has pioneered an interventional neuromodulation platform and is developing the world’s first minimally-invasive motor neuroprosthesis, the Stentrode. The company is also developing endovascular neuromodulation solutions for the potential treatment of Parkinson’s disease, epilepsy, depression and hypertension, among other disorders.
July-2022: Bloomberg reported that Synchron implanted a device into the brain of an ALS patient at Mount Sinai West medical center on July 6,.
Visit website: https://www.synchronmed.com/
People at Synchron
Synchron's BCI device offers new hope for communication in paralyzed patients
IEEE Spectrum - 20-Dec-2023
Non-invasive neural device leads via blood vessel while Neuralink awaits human trialsRead more...
Synchron’s brain implant that helps turn thoughts into text
CNBC - 18-Feb-2023
Stentrode is an endovascular electrode array implanted through the blood vesselsRead more...
Synchron gets investment from Neuralink cofounder
Futurism - 07-Feb-2022
Appears to be ahead in the race as already started human trialsRead more...
Synchron helps paralysed patients control digital devices with thoughts alone
MobiHealthNews - 29-Jul-2021
Implantable brain computer interface received FDA approval for human trials in USRead more...